Clinical Trials Browser

Completed × encorafenib × Clear all

NCT05039177 2026-03-25

HERKULES-3

Phase 1/2 Completed

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 2 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT05510895 2025-10-01

NeoBRAF

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05304546 2025-07-22

MK3475-C01

Phase 2 Completed

Melanoma, Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

Phase 2 Completed

48 enrolled 24 charts

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT05004350 2025-04-15

NAUTICALCRC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT05260684 2025-03-06

OCEANMIST

716 enrolled 10 charts

Melanoma

NCT01436656 2024-10-28

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Phase 1 Completed

107 enrolled 49 charts

DermatologicGastrointestinal

Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Phase 1/2 Completed

17 enrolled 9 charts

Advanced BRAF Mutant Cancers

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1 Completed

56 enrolled 158 charts

Melanoma

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Phase 2 Completed

7 enrolled 9 charts

Melanoma

NCT05003622 2024-06-24

OCEANI

Phase 1 Completed

3 enrolled 26 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

Phase 2 Completed

Melanoma

NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Phase 1/2 Completed

189 enrolled 44 charts

Other solid neoplasm

Solid Tumors Harboring a BRAF V600 Mutation

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT02928224 2023-12-21

BEACON CRC

Phase 3 Completed

702 enrolled 82 charts 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT02834364 2023-11-24

GMMG-BIRMA

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Phase 1 Completed

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT01719380 2021-06-23

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Phase 2 Completed

156 enrolled 41 charts

Gastrointestinal

Colorectal Neoplasms

NCT02902042 2021-02-16

IMMU-TARGET

Phase 1/2 Completed

Melanoma

NCT02278133 2017-10-09

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Phase 1/2 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms